$27.80
8.26% yesterday
Nasdaq, Sep 03, 10:15 pm CET
ISIN
US04280A1007
Symbol
ARWR

Arrowhead Pharmaceuticals, Inc. Stock price

$27.80
+11.34 68.84% 1M
+10.09 56.97% 6M
+9.00 47.87% YTD
+4.89 21.34% 1Y
-11.62 29.48% 3Y
-9.26 24.99% 5Y
+22.32 407.30% 10Y
+1.40 5.30% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+2.12 8.26%

Key metrics

Basic
Market capitalization
$3.8b
Enterprise Value
$3.2b
Net debt
positive
Cash
$898.2m
Shares outstanding
138.1m
Valuation (TTM | estimate)
P/E
negative | 107.6
P/S
6.7 | 4.5
EV/Sales
5.6 | 3.6
EV/FCF
negative
P/B
7.4
Financial Health
Equity Ratio
16.3%
Return on Equity
-323.3%
ROCE
-9.1%
ROIC
-26.1%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$573.0m | $795.7m
EBITDA
$-85.4m | $119.3m
EBIT
$-108.0m | $186.5m
Net Income
$-148.4m | $33.0m
Free Cash Flow
$-17.6m
Growth (TTM | estimate)
Revenue
2,815.9% | 22,312.7%
EBITDA
83.9% | 120.5%
EBIT
80.3% | 131.0%
Net Income
72.4% | 105.5%
Free Cash Flow
96.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-14.9% | 15.0%
EBIT
-18.8%
Net
-25.9% | 4.1%
Free Cash Flow
-3.1%
More
EPS
$-1.1
FCF per Share
$-0.1
Short interest
12.1%
Employees
609
Rev per Employee
$10.0k
Show more

Is Arrowhead Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Arrowhead Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

15x Buy
71%
6x Hold
29%

Analyst Opinions

21 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Arrowhead Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
573 573
2,816% 2,816%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 123 123
14% 14%
21%
- Research and Development Expense 536 536
21% 21%
93%
-85 -85
84% 84%
-15%
- Depreciation and Amortization 23 23
29% 29%
4%
EBIT (Operating Income) EBIT -108 -108
80% 80%
-19%
Net Profit -148 -148
72% 72%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Arrowhead Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arrowhead Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
about 8 hours ago
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Citi's 2025 Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Very much and welcome again to the Citi Biopharma Conference in Boston. H...
Positive
Seeking Alpha
about 11 hours ago
Arrowhead stock is a Strong Buy due to significant pipeline progress, especially the upcoming FDA PDUFA review date of plozasiran for familial chylomicronemia syndrome. The PALISADE phase 3 trial for plozasiran showed robust efficacy in reducing triglycerides and acute pancreatitis risk, leading to an FDA PDUFA review date of November 18, 2025. Ongoing late-stage studies for severe hypertriglyc...
Positive
Investors Business Daily
one day ago
Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug, sending Arrowhead stock surging.
More Arrowhead Pharmaceuticals, Inc. News

Company Profile

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Head office United States
CEO Christopher Anzalone
Employees 609
Founded 1989
Website arrowheadpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today